Scholarlink

Background <p>Breast cancer is the leading cancer among females in Sri Lanka. Understanding quality of life (QoL) among survivors is essential for comprehensive cancer care. This study aimed to assess QoL and identify associated factors among breast cancer survivors treated at a university hospital in Sri Lanka.</p> Methods <p>This cross-sectional study included 112 breast cancer survivors treated between May 2019 and May 2022. QoL was assessed using validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ-C30 and QLQ-BR23). Descriptive statistics, correlation analyses, and linear regression models were used to identify factors associated with QoL domains.</p> Results <p>The mean age of survivors was 61.15 (± 13.42) years. The mean Quality of Life (QoL) domain score of the EORTC QLQ-C30 was 68.2 (SD 17.5), indicating generally good QoL among participants. Age was significantly negatively correlated with overall QoL (<i>r</i> = -0.31, <i>p</i> = 0.001) and physical functioning (<i>r</i> = -0.29, <i>p</i> = 0.002), and positively correlated with systemic therapy side effects (<i>r</i> = 0.24, <i>p</i> = 0.011) and sexual functioning (<i>r</i> = 0.22, <i>p</i> = 0.020). Larger tumor size was associated with lower physical functioning (<i>r</i> = -0.23, <i>p</i> = 0.015) and poorer body image (<i>p</i> = 0.018). A higher number of radiotherapy fractions was associated with lower sexual functioning (<i>r</i> = -0.26, <i>p</i> = 0.006).</p> Conclusions <p>Breast cancer survivors demonstrated generally good QoL, with age emerging as a significant determinant. These findings highlight the importance of age-appropriate supportive interventions and integrating QoL assessment into routine survivorship care in Sri Lanka. Clinicians should focus on addressing physical functioning in older survivors and managing treatment side effects to optimize QoL across all age groups.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Quality of life in breast cancer survivors: insights from a university hospital in Sri Lanka

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月25日

查看全文
  • Ranga Perera,
  • Dimalshi Wijethunga,
  • Minoshi Perera,
  • Chathura Abeywickrama,
  • Maheshi P. Lakshman,
  • Hansika Gunawardana,
  • Prasanna Herath

摘要

Background

Breast cancer is the leading cancer among females in Sri Lanka. Understanding quality of life (QoL) among survivors is essential for comprehensive cancer care. This study aimed to assess QoL and identify associated factors among breast cancer survivors treated at a university hospital in Sri Lanka.

Methods

This cross-sectional study included 112 breast cancer survivors treated between May 2019 and May 2022. QoL was assessed using validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ-C30 and QLQ-BR23). Descriptive statistics, correlation analyses, and linear regression models were used to identify factors associated with QoL domains.

Results

The mean age of survivors was 61.15 (± 13.42) years. The mean Quality of Life (QoL) domain score of the EORTC QLQ-C30 was 68.2 (SD 17.5), indicating generally good QoL among participants. Age was significantly negatively correlated with overall QoL (r = -0.31, p = 0.001) and physical functioning (r = -0.29, p = 0.002), and positively correlated with systemic therapy side effects (r = 0.24, p = 0.011) and sexual functioning (r = 0.22, p = 0.020). Larger tumor size was associated with lower physical functioning (r = -0.23, p = 0.015) and poorer body image (p = 0.018). A higher number of radiotherapy fractions was associated with lower sexual functioning (r = -0.26, p = 0.006).

Conclusions

Breast cancer survivors demonstrated generally good QoL, with age emerging as a significant determinant. These findings highlight the importance of age-appropriate supportive interventions and integrating QoL assessment into routine survivorship care in Sri Lanka. Clinicians should focus on addressing physical functioning in older survivors and managing treatment side effects to optimize QoL across all age groups.